

Activated neutrophils degrade cartilage endplates

Irina Heggli^{*1}, Mohamed Habib², Justin Scheer³, Nick Herger¹, Tamara Mengis¹, Borbala Aradi-Vegh¹, Christoph J. Laux⁴, José Miguel Spirig⁴, Florian Wanivenhaus⁴, Michael Betz⁴, Christopher P. Ames³, Mazda Farshad⁴, Oliver Distler¹, Aaron J. Fields², Stefan Dudli¹

¹Center of Experimental Rheumatology, Balgrist Campus, University Hospital Zurich and Balgrist University Hospital, University of Zurich, Switzerland; ²Department of Orthopaedic Surgery, University of California San Francisco, San Francisco, CA, USA, ³Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA, ⁴Department of Orthopedics, Balgrist University Hospital, University of Zurich, Switzerland: irina.Heggli@usz.ch

Introduction

Modic changes (MC):

- Painful vertebral bone marrow lesions that occur around a degenerated intervertebral disc (IVD) and colocalize with endplate damage.
- Signs for neutrophil contribution in MC^{1,2}:** Granulation tissue at bone-disc junction and dysregulated neutrophil maturation in MC bone marrow

In rheumatoid arthritis: **Activated neutrophils** mediate articular **cartilage**³

Little is known about the role of neutrophils in Modic changes and disc tissue damage


Aims

- To show that MC1 bone marrow neutrophils are activated
- To discover the effects of activated blood neutrophils on cartilage endplate (CEP) composition

Methods

MC1 bone marrow derived neutrophil activation assessment

- Isolation of MC1 and intra-patient control bone marrow neutrophils from patients undergoing spinal fusion (n = 5+5)
- RNA isolation, sequencing, bioinformatic overrepresentation analysis (ORA) and gene set enrichment analysis (GSEA)
- Measurement of the neutrophil activation marker CD66b with flow cytometry (n = 3+3) (Figure 1)



Neutrophil-mediated cartilage endplate (CEP) damage model

- Collection of 3 lumbar circular CEP biopsies per patient (patients n=6); CEP biopsies were halved and exposed to activated (100nM PMA, 3h) and non-activated neutrophil supernatant of one donor
- CEP tissue released sulphated glycosaminoglycan (sGAG) and hydroxyproline (as collagen release measure) were assayed using dimethylmethylene blue and chloramine-T assay (release from half-biopsy specific control was set to 100 %) (Figure 2)




Figure 2. Neutrophil-mediated cartilage endplate (CEP) damage model.

Results


1. MC1 bone marrow neutrophils have an activated pro-inflammatory phenotype

RNA sequencing:

- 185 differentially expressed genes** between MC1 and control bone marrow neutrophils
- ORA: Top 5 upregulated gene ontology (GOs) in MC1:** All related to neutrophil activation (Figure 3a).
- GSEA: Top enriched hallmark gene sets in MC1:** “inflammatory response” (p=0.001, normalized enrichment score (NES) =1.6) (Figure 3b), “IFN- α response (p=0.0, NES=2.2), and IFN- γ response (p=0.0, NES=1.9)

Flow cytometric analysis of CD66b expression:


- Significantly more activated neutrophils (measured as CD66^{high} expression) in MC1 (control: 43.1 % \pm 15.7, MC1: 54.1 % \pm 16.7, p=0.018) (Figure 3c).



2. Activated blood neutrophils degrade human CEPs

Exposure of CEP tissues to conditioned medium from activated neutrophils:

- Significant increased sGAG release from CEP tissues in a dose-dependent manner (Figure 4)**
 - 25 mio/ml:** 380.1 % \pm 177, p = 0.012;
 - 12.5 mio/ml:** 123.7 % \pm 22.3, p = 0.048
 - Relative sGAG release: **3.1-fold higher** in the CEPs exposed to supernatant from 25 mio/ml neutrophils compared to 12.5 mio/ml neutrophils (25 vs. 12.5 mio/ml: p = 0.022)
- No significant effect of neutrophil supernatant on hydroxyproline release



Discussion & Conclusion

Implications

Activated MC1 bone marrow neutrophils may promote and exacerbate CEP damage, thereby **facilitating enhanced inflammatory disc/marrow crosstalk in MC1.**

CEP damage may also **increase nerve fibre density.**



These findings reveal a **potential novel MC1 pathomechanism** and could have implications for **treatment strategies to mitigate CEP damage in MC1.**

- MC1 bone marrow neutrophils** have an **activated phenotype**
- Activated peripheral **blood neutrophils** **degrade proteoglycans** from CEPs
- sGAG** released from CEPs exposed to **activated neutrophil** supernatant for only 18 hours is **similar to the amount of sGAG lost in vivo over 20 years** of natural ageing
- Whether activated MC1 bone marrow neutrophils can degrade CEP tissue remains to be elucidated